United States Patent 6,217,866: Claim Validity, Scope, and Competitive Landscape for Anti-EGFR Monoclonal Antibody Plus Chemotherapy

What does US 6,217,866 claim, in enforceable scope terms?

US 6,217,866 is directed to combination therapy for “human tumor cells” that (1) express human EGF receptors (EGFR/ErbB1) and (2) are mitogenically stimulated by human EGF. The core claim structure is consistent across both method and composition categories:

Administer (or provide) a monoclonal antibody (mAb) + a separate anti-neoplastic agent
The mAb is not conjugated to the anti-neoplastic agent
The mAb binds the extracellular domain of the human EGF receptor
The mAb inhibits EGF binding to the EGFR (functionally competing with EGF)
The anti-neoplastic agent can be doxorubicin or cisplatin
A preferred exemplification identifies the mAb as “108” produced by hybridoma cell line ATCC HB 9764
The antibody is further characterized by its ability to inhibit KB oral epidermoid carcinoma cells by binding the extracellular EGFR domain in an antigen-antibody complex

Claim set (as provided)

Claim 1 (method): combination administration with required functional and binding features; antibody blocks EGF-EGFR binding; not conjugated to chemotherapy.
Claims 2-3: chemotherapy options: doxorubicin and cisplatin.
Claim 4: antibody identity: mAb 108 from ATCC HB 9764.
Claim 5: functional cell-line characterization: inhibits KB cells by extracellular EGFR binding.
Claims 6-9 (composition): same limitations but framed as a therapeutic composition with pharmaceutical carrier; includes antibody identity and chemotherapy options.

Practical reading of scope

The enforceable “center of gravity” is the combination of:

Unconjugated anti-EGFR mAb that blocks EGF binding (competitive or steric inhibition at the extracellular domain), and
Standard cytotoxics (explicitly doxorubicin, cisplatin), co-administered (or formulated together) to inhibit tumor growth in EGFR-driven, EGF-stimulated contexts.

The claims do not require:

specific dosing schedules (simultaneous vs sequential is not stated in the claim text you provided),
specific routes,
specific tumor indications beyond “human tumor cells” meeting the EGFR and EGF-stimulation criteria,
specific affinity, epitope mapping beyond “extracellular domain,” or
any internalization mechanism (the functional requirement is inhibition of EGF binding, not receptor downregulation).

That omission broadens claim reach for any antibody that meets the binding and functional constraints, regardless of whether it induces internalization or ADCC, as long as EGF binding is inhibited.

How strong are the claims against known EGFR-targeting prior art?

A critical challenge is that US 6,217,866’s combination premise tracks a pattern that became commercially and scientifically established early: EGFR-targeting antibodies paired with chemotherapy. The novelty therefore hinges on claim-specific limitations, especially:

Antibody not conjugated to chemotherapy
Antibody binds extracellular EGFR domain
Antibody inhibits EGF binding
Specific embodiment (mAb 108 from ATCC HB 9764)
Explicit chemotherapeutics: doxorubicin or cisplatin (for dependent claims)

Key validity pressure points

Functionally defined antibody limitation (“inhibit binding of EGF to the EGFR”)
- This is a functional constraint that can be satisfied by multiple prior anti-EGFR mAbs that compete with EGF or sterically block EGF binding at the extracellular domain.
- For validity, that constraint is double-edged: it adds a limitation, but it also invites a prior-art mapping exercise where any earlier mAb that blocks EGF binding can anticipate.
“Not conjugated”
- This narrows over conjugate approaches (immunotoxins, drug-antibody conjugates).
- It still preserves scope for broad “combination regimen” strategies.
Combination with doxorubicin/cisplatin
- These are classic cytotoxics used across oncology regimens.
- If the prior art already teaches combining EGFR blockade with chemotherapy in general, the dependent claim narrowing to particular cytotoxics may not rescue novelty unless the combination itself is not taught or is not obvious.
mAb 108 / ATCC HB 9764 identification
- Dependent claims that identify the antibody by hybridoma deposit typically tighten the scope toward a specific biological source.
- However, enforceability still depends on whether others could argue non-equivalence: if their antibody binds extracellular EGFR and blocks EGF binding but differs from mAb 108, it may fall outside the literal scope of dependent claims but could still fall within Claim 1’s functional requirements.

What does a competitor need to avoid infringement?

Because Claim 1 is framed broadly around antibody function and binding location (extracellular domain) rather than a specific antibody sequence or epitope, designing around Claim 1 is difficult if the competitor’s mAb blocks EGF binding. Avoidance depends on breaking at least one required limitation.

“Infringement-relevant” elements

Claim element	What the claim requires	Design-around handle
Antibody binds extracellular EGFR	extracellular domain binding	Use an antibody that binds but does not meet “inhibits EGF binding” requirement
Antibody inhibits EGF binding	must block EGF attachment to EGFR	Use an antibody that binds EGFR but does not block EGF binding (for example, non-competitive epitope)
Antibody not conjugated	no covalent conjugate to chemo	Use a conjugate (immunotoxin/DAC) approach or ensure no “method comprising administering” both as claimed could apply depending on regimen characterization
Anti-neoplastic agent present	effective amount of anti-neoplastic agent	Employ different cytotoxic agent and challenge “effective amount” and combination teaching in obviousness rather than literal elements (dependent claims 2-3 require doxorubicin/cisplatin explicitly)

In practice, the most direct way to avoid Claim 1 is to deploy an antibody that binds EGFR but does not inhibit EGF binding (non-competitive or epitope-distal antibodies), or to target a different receptor/ligand relationship.

Dependent claims create narrower constraints

Claims 2 and 3 are limited to doxorubicin and cisplatin, respectively.
Claims 4 and 9 tie to mAb 108 from ATCC HB 9764. So a competitor using other chemotherapies and/or an antibody that differs from mAb 108 can reduce risk versus the dependent claims, while Claim 1 remains the most important exposure.

Where does the prior-art and landscape sit (high-level commercial context)?

Even without invoking any specific “yes/no” novelty conclusions for each anticipated reference, the commercial reality matters: EGFR blockade with monoclonal antibodies and small-molecule inhibitors became a large category. In that context, US 6,217,866 is best viewed as a combination-regimen patent anchored in a particular functional antibody property (EGF-binding inhibition) and pairing with classic cytotoxics.

Landscape positioning by claim type

Claim 1 and 6 (broad method/composition): covers “anti-EGFR mAb that blocks EGF binding” + chemotherapy, unconjugated.
Claims 2-3 and 7-8: specifies chemotherapy agents (doxorubicin/cisplatin).
Claims 4-5 and 9: identifies mAb 108 deposited as ATCC HB 9764 and ties it to KB cell growth inhibition.

This structure typically leads to two litigation dynamics:

Broad Claim 1 drives most infringement arguments and most invalidity mapping because it covers many functionally similar antibodies.
Dependent claims can be targeted for narrower claim construction and stronger biological identification defenses, but they may not eliminate exposure if the accused product matches Claim 1’s functional antibody requirements.

Critical review of the claims as drafting and enforcement assets

1) Functional antibody limitation is likely the battleground

The claims require the antibody to:

bind the extracellular EGFR domain, and
inhibit EGF binding.

This is a clear functional criterion that can be tested in vitro. It is also a classic source of prior-art overlap: multiple EGFR antibodies block EGF binding.

From an enforcement standpoint, this can be advantageous because you can assay EGF binding inhibition as evidence. From a validity standpoint, it increases the chance that earlier EGFR antibodies satisfy the same functional constraints.

2) “Human tumor cells … mitogenically stimulated by EGF” is broad and hard to disprove

The tumor cell prerequisite is essentially a biological correlation. In many EGFR-driven tumors, EGF-mediated mitogenesis exists or can be induced in vitro. This makes it difficult to invalidate based on failure of the biological condition, unless the accused regimen targets contexts where the growth is not EGF-mediated.

3) Combination claims may be vulnerable to obviousness

If EGFR blockade and chemotherapy were separately known and the combination was predictable for EGFR-driven cancers, a factfinder can treat the combination as an optimization rather than a non-obvious leap. The patent’s novelty then depends on a specific synergy that is tied to the antibody’s EGF-binding inhibition mechanism. The claim text you provided does not state a synergy requirement.

4) The “not conjugated” requirement narrows scope, but does not eliminate obviousness risk

Not conjugated excludes a class of drug-antibody conjugates, but it still leaves ordinary coadministration and combination regimen logic.

How to map competitive risk within the landscape (claim-to-product logic)

A disciplined risk screen should classify each competing asset by whether it meets the functional antibody requirements and by what chemotherapy it combines.

Risk screen matrix

Competitor therapy element	Meets Claim 1?	How it changes exposure
EGFR antibody binds extracellular EGFR and blocks EGF binding	Yes, likely core match	High risk for Claim 1
EGFR antibody binds EGFR but does not block EGF binding	No	Typically lowers risk for Claim 1, may still implicate non-infringing but functionally different mechanisms
Antibody-drug conjugate (ADC) form	Unclear from Claim text provided	“Not conjugated” can become a strong argument if covalently linked
EGFR blockade combined with doxorubicin/cisplatin	Depends on exact chemotherapy	Raises risk for dependent claims; Claim 1 exposure remains if antibody matches
Uses other chemotherapy agents	May avoid dependent 2-3/7-8	Claim 1 exposure persists because Claim 1 does not specify doxorubicin/cisplatin

Key Takeaways

US 6,217,866 is anchored on EGFR extracellular domain binding plus a functional constraint that the antibody inhibits EGF binding, combined with unconjugated chemotherapy to inhibit EGFR-driven tumor growth.
The broadest exposure is Claim 1 (and composition Claim 6) because it is not limited to doxorubicin/cisplatin or to a specific antibody beyond functional extracellular EGFR binding and EGF-binding inhibition.
Dependent claims narrow risk: doxorubicin/cisplatin (Claims 2-3, 7-8) and mAb 108 from ATCC HB 9764 (Claims 4-5, 9). Competitors can reduce dependent-claim risk by changing chemotherapy and/or using a different antibody, but Claim 1 remains the central infringement and invalidity target.
Drafting strength is the testable functional requirement (inhibition of EGF binding). Drafting weakness is that this requirement can be met by multiple earlier anti-EGFR antibodies, increasing prior-art/obviousness mapping likelihood.
For competitive positioning, the decisive question for any EGFR mAb program is whether the antibody blocks EGF binding to EGFR; if it does, the patent’s combination framing can become a structural risk.

FAQs

1) What is the single most important limitation in US 6,217,866 for infringement?
The antibody must bind the extracellular domain of human EGFR and must inhibit EGF binding to the EGFR.

2) Does the patent require a covalent antibody-drug conjugate?
No. The claims require the antibody is not conjugated to the anti-neoplastic agent.

3) Are doxorubicin and cisplatin required for all claims?
No. They appear in dependent claims (Claims 2-3 and 7-8). Claim 1/6 allow an anti-neoplastic agent generally.

4) How does the mAb identity “108” (ATCC HB 9764) affect claim scope?
It narrows dependent claims (notably Claims 4 and 9) to a specific deposited hybridoma-derived monoclonal antibody, while Claim 1 can still be implicated by other antibodies meeting the functional criteria.

5) What is the practical test for the antibody limitation?
The claims require inhibition of EGF binding to EGFR, which is assessable using binding competition/attachment assays using extracellular EGFR binding.

References

[1] United States Patent 6,217,866.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	6,217,866	2015-06-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007	6,217,866	2015-06-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
Netherlands	300353	⤷ Start Trial
Netherlands	300351	⤷ Start Trial
Netherlands	300350	⤷ Start Trial
Netherlands	300167	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 6,217,866

Summary for Patent: 6,217,866